X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1462) 1462
Publication (101) 101
Newsletter (52) 52
Book Review (38) 38
Newspaper Article (13) 13
Book Chapter (5) 5
Conference Proceeding (4) 4
Magazine Article (3) 3
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
liraglutide (1274) 1274
index medicus (938) 938
humans (898) 898
diabetes mellitus, type 2 - drug therapy (637) 637
type 2 diabetes (608) 608
male (584) 584
endocrinology & metabolism (545) 545
diabetes (513) 513
female (460) 460
glucagon-like peptide 1 - analogs & derivatives (442) 442
glucagon-like peptide-1 (421) 421
hypoglycemic agents - therapeutic use (416) 416
hypoglycemic agents - administration & dosage (375) 375
middle aged (374) 374
exenatide (317) 317
insulin (313) 313
animals (307) 307
glucose (301) 301
glucagon (283) 283
treatment outcome (269) 269
obesity (255) 255
glucagon-like peptide 1 - therapeutic use (251) 251
hypoglycemic agents - adverse effects (245) 245
diabetes mellitus, type 2 - blood (244) 244
glycemic control (242) 242
drug therapy (241) 241
adult (238) 238
aged (238) 238
metformin (236) 236
research (224) 224
safety (224) 224
dosage and administration (222) 222
care and treatment (219) 219
pharmacology & pharmacy (216) 216
analysis (213) 213
diabetes mellitus (206) 206
glp-1 (206) 206
blood glucose - drug effects (204) 204
clinical trials (196) 196
glucagon-like peptide 1 - administration & dosage (193) 193
peptides (191) 191
liraglutide - administration & dosage (189) 189
liraglutide - therapeutic use (177) 177
efficacy (174) 174
diabetes therapy (170) 170
open-label (166) 166
hypoglycemic agents - pharmacology (162) 162
medicine, general & internal (161) 161
blood glucose - metabolism (160) 160
mice (156) 156
drug therapy, combination (152) 152
drug administration schedule (149) 149
double-blind (147) 147
health aspects (147) 147
risk factors (141) 141
glucagon-like peptide-1 receptor - agonists (139) 139
internal medicine (139) 139
body weight (138) 138
glucagon-like peptide-1 receptor (136) 136
glucagon-like peptide 1 (135) 135
hypoglycemia (135) 135
double-blind method (131) 131
glycated hemoglobin a - metabolism (128) 128
glucagon-like peptide 1 - pharmacology (123) 123
peptides - therapeutic use (122) 122
glucagon-like peptide 1 - adverse effects (121) 121
rats (121) 121
hypoglycemic agents (120) 120
obesity - drug therapy (119) 119
weight loss - drug effects (119) 119
hyperglycemia (117) 117
liraglutide - pharmacology (116) 116
insulin resistance (115) 115
abridged index medicus (113) 113
weight loss (112) 112
peptides - administration & dosage (111) 111
type 2 diabetes mellitus (108) 108
venoms - therapeutic use (108) 108
body mass index (107) 107
body weight - drug effects (107) 107
receptors, glucagon - agonists (107) 107
dextrose (106) 106
mellitus (105) 105
physiological aspects (103) 103
glycated hemoglobin a - analysis (102) 102
rodents (102) 102
diabetes mellitus, type 2 - metabolism (99) 99
beta-cell function (98) 98
medicine, research & experimental (98) 98
medicine & public health (97) 97
type-2 diabetes-mellitus (97) 97
glycosylated hemoglobin (95) 95
venoms - administration & dosage (92) 92
sitagliptin (91) 91
dose-response relationship, drug (90) 90
diabetes mellitus, type 2 - complications (89) 89
patients (88) 88
metabolism (87) 87
original (87) 87
hypoglycemia - chemically induced (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1501) 1501
German (9) 9
Spanish (5) 5
French (4) 4
Japanese (4) 4
Chinese (3) 3
Czech (2) 2
Korean (2) 2
Danish (1) 1
Hungarian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2317 - 2325
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
Aims: To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in people with type 2 diabetes. Materials and methods: We... 
GLP | type 2 diabetes | network meta‐analysis | systematic review | 1 analogue | network meta-analysis | GLP-1 analogue | GLYCEMIC CONTROL | EXENATIDE TWICE | ONCE-DAILY LIXISENATIDE | OPEN-LABEL | EUROPEAN ASSOCIATION | NETWORK METAANALYSIS | METFORMIN-TREATED PATIENTS | BASAL INSULIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ANALOG LIRAGLUTIDE | OPEN-LABEL | INHIBITOR SITAGLIPTIN | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 2, pp. 153 - 157
Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs. We examined... 
pharmacokinetics | dipeptidyl peptidase-4 inhibitor | glucagon-like peptide-1 receptor agonist | target molecular binding occupancy | pharmacodynamics | Dipeptidyl peptidase-4 inhibitor | Pharmacodynamics | Pharmacokinetics | Glucagon-like peptide-1 receptor agonist | Target molecular binding occupancy | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOLOGY & PHARMACY | PROMOTES SATIETY | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Peptides - pharmacokinetics | Nitriles - pharmacokinetics | Peptides - administration & dosage | Peptides - metabolism | Hypoglycemic Agents - administration & dosage | Pyrrolidines - metabolism | Adamantane - therapeutic use | Adamantane - administration & dosage | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Piperidines - metabolism | Pyrrolidines - pharmacokinetics | Adamantane - metabolism | Models, Molecular | Uracil - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Liraglutide - therapeutic use | Venoms - therapeutic use | Ligands | Venoms - metabolism | Sitagliptin Phosphate - pharmacokinetics | Venoms - pharmacokinetics | Nitriles - therapeutic use | Liraglutide - metabolism | Sitagliptin Phosphate - metabolism | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Molecular Targeted Therapy | Pyrrolidines - therapeutic use | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Liraglutide - pharmacokinetics | Uracil - administration & dosage | Venoms - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - metabolism | Piperidines - pharmacokinetics | Adamantane - pharmacokinetics | Nitriles - metabolism | Reproducibility of Results | Diabetes Mellitus, Type 2 - blood | Algorithms | Piperidines - therapeutic use | Sitagliptin Phosphate - therapeutic use | Uracil - metabolism | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Uracil - pharmacokinetics | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - therapeutic use | Uracil - analogs & derivatives | Binding | Drugs | Effectiveness | Peptidase | Glucagon | Diabetes mellitus | Theoretical analysis | Low level | Receptors | Inhibitors | Nitric oxide | Occupancy | Hemoglobin | Agonists | Glucagon-like peptide 1 | Drug dosages
Journal Article
Diabetes Care, ISSN 0149-5992, 2013, Volume 36, Issue 8, pp. 2254 - 2261
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Journal Article
DIABETES CARE, ISSN 0149-5992, 05/2018, Volume 41, Issue 5, pp. 1009 - 1016
OBJECTIVE In patients with uncontrolled type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating... 
FIXED-RATIO COMBINATION | MANAGEMENT | ENDOCRINOLOGY & METABOLISM | HYPOGLYCEMIA | GLP-1 RECEPTOR AGONIST | INERTIA | LIRAGLUTIDE IDEGLIRA | DEGLUDEC | DEGLUDEC/LIRAGLUTIDE | Glycated Hemoglobin A - analysis | Humans | Middle Aged | Male | Metformin - adverse effects | Insulin Glargine - administration & dosage | Insulin Aspart - administration & dosage | Hypoglycemic Agents - administration & dosage | Adult | Female | Metformin - administration & dosage | Drug Therapy, Combination | Insulin Glargine - adverse effects | Insulin - administration & dosage | Treatment Outcome | Blood Glucose - drug effects | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Liraglutide - adverse effects | Aged | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin Aspart - adverse effects | Drug Combinations | Type 2 diabetes | Care and treatment | Control | Blood sugar | Analysis | Hemoglobin | Diagnosis | Research | Hypoglycemia | Drug therapy | Insulin | Body weight | Diabetes mellitus | Clinical trials | Body weight loss | Glucose | Patients | Randomization | Safety engineering | Research design | Safety | Diabetes | Metformin | Diabetes mellitus (non-insulin dependent)
Journal Article
Journal Article